Baxa Addresses Health-System Capital Shortage with New Programs for IntelliFlowRx™ and IntelliFill i.v.®

Share Article

New Baxa IntelliSource™ program eliminates capital investment requirements allowing rapid deployment of patient safety improvements using IntelliFlowRx and IntelliFill i.v.. Health-system pharmacies now have access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.

Baxa Corporation announces the launch of a new program for sourcing its IntelliFill i.v. Automation and IntelliFlow Rx Pharmacy Workflow Manager products. The Baxa IntelliSource™ program offers health-system pharmacies access to the automation and software they need to ensure that each dose dispensed is safe and accurate - without making capital investments, paying one-time setup fees or signing capital leases.

"Our goal was to make it easy for health systems to improve their pharmacy operations," notes Greg Baldwin, Baxa CEO. "We feel that patient safety improvements shouldn't take a back seat to this economy's capital crunch. The IntelliSource pricing model makes it easy for health systems to install the latest pharmacy technology, eliminating the need for capital investment and providing manageable monthly fees for access."

Using the IntelliSource model, health systems can implement the IntelliFlowRx pharmacy workflow manager without capital expenditures or lump-sum setup charges. This allows facilities of all sizes the ability to use barcode drug identification, automated dose preparation workflow management and dose checking safety features provided by IntelliFlowRx. In addition, the Baxa IntelliSource program makes it easy for health systems to get started. Once consultation on pharmacy workflow is completed, systems can be installed without the lengthy delays associated with capital allocation procedures.

For the IntelliFill i.v. System, using IntelliSource allows health-systems to implement leading-edge automation for IV preparation and labeling without capital investment. That provides access for the advanced technology used to prepare nearly 27 million patient doses to a greater number of North American health systems.

Both the IntelliFlowRx and the IntelliFill i.v. Systems provide demonstrated improvements in pharmacy dose management and IV room productivity. These products promote best practices for pharmacy operations, reduce drug waste, ensure dose accuracy and improve patient safety - one dose at a time.

Baxa Corporation, an exhibitor at the 44th American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting in Las Vegas, will provide details of the IntelliSource program in their booth (101) at the Venetian Hotel and Sands Expo Center December 6th - 10th, 2009.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications. Key products include the PadLock® Set Saver, Rapid-Fill™ Automated Syringe Fillers, ExactaMed® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, the IntelliFlow™ Rx System and ExactaMix™ Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Its subsidiary FHT, Inc. produces the IntelliFilli.v.® automation. Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide. Further information is available at http://www.baxa.com

Contacts:

Marian Robinson, Vice President, Marketing
Baxa Corporation http://www.baxa.com 800.567.2292 ext. 2157 or 303.617.2157

Maggie Chamberlin Holben, APR
Absolutely Public Relations http://www.absolutelypr.com 303.984.9801 or 303.669.3558

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

MARIAN ROBINSON

MAGGIE HOLBEN
Visit website